Allelic variants of immune response genes in children with infectious complications during the treatment of acute leukemia

• Published in: Molecular biology (New York) Vol. 51; no. 2; pp. 263 - 268
• Main Authors: Avdonina, M. A., Abramov, I. S., Ammour, Y. I., Nasedkina, T. V.
• Format: Journal Article
• Language: English
• Published: Moscow Pleiades Publishing 01.03.2017; Springer Nature B.V
• Subjects: Amino acids; Biochemistry; Biomedical and Life Sciences; Chemotherapy; Children; Complications; Gene regulation; Genetic markers; Genomes; Genomics. Transcriptomics; Human Genetics; Immune response; Infections; Interleukin 7 receptors; Leukemia; Life Sciences; Protein-tyrosine-phosphatase; Single-nucleotide polymorphism; TLR4 protein; Toll-like receptors; targeted sequencing; immune system genes; polymorphism; acute leukemia
• ISSN: 0026-8933; 1608-3245
• DOI: 10.1134/S0026893317020042

Infectious complications that arise during the treatment of children with acute leukemia with chemotherapeutic agents at high doses represent a serious problem in oncohematology. To find genetic conditions that may lead to the development of postchemotherapy infections, the genomes of 12 children with acute leukemia who had severe infectious complications during therapy were examined. At the same time, the coding regions of 17 genes involved in the regulation of the immune response were determined by massive parallel sequencing. The analysis revealed 39 nonsynonymous SNPs that lead to amino acid substitutions, including the following informative genetic markers: PTPN22 c.1858C>T (rs2476601), TLR4 c.896A>G (rs4986790) and TLR4 c.1196C>T (rs4986791), IL7R c.197T>C (rs1494555) and IL7R c.412G>A (rs1494558). The results of massive parallel sequencing were validated by Sanger sequencing. The identification of genetic markers associated with the predisposition to infectious complications may allow one to assess the individual risk of the severe infection development in children with acute leukemia during the treatment with chemotherapeutic agents and to begin the development of personalized approaches to anticancer therapy.